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Background: Accelerated hypofractionated radiotherapy can shorten total treatment time and overcome the
accelerated repopulation of tumour cells during radiotherapy. This therapeutic approach has demonstrated good
efficacy in the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the optimal fractionation
scheme remains uncertain. The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of
accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in
combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC.
Methods: Previously untreated cases of unresectable stage III NSCLC received accelerated hypofractionated 3-DCRT,
delivered at 3 Gy per fraction, once daily, with five fractions per week. The starting dose was 66 Gy and an increment of
3 Gy was utilized. Higher doses continued to be tested in patient groups until the emergence of dose-limiting toxicity
(DLT). The MTD was regarded as the dose that was one step below the dose at which DLT occurred. Patients received
at least one cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP.
Results: A total of 13 patients were enrolled and progressed through three dose escalation groups: 66 Gy, 69 Gy, and
72 Gy. No treatment-related deaths occurred. The major adverse events included radiation oesophagitis, radiation
pneumonitis, and neutropenia. Nausea, fatigue, and anorexia were commonly observed, although the magnitude of
these events was typically relatively minor. Among the entire group, four instances of DLT were observed, including
two cases of grade 3 radiation oesophagitis, one case of grade 3 radiation pneumonitis, and one case of grade 4
neutropenia. All of these cases of DLT occurred in the 72 Gy group. Therefore, 72 Gy was designated as the DLT dose
level, and the lower dose of 69 Gy was regarded as the MTD.
Conclusions: For unresectable stage III NSCLC 69 Gy (at 3 Gy/fraction) was the MTD of accelerated hypofractionated
3-DCRT administered in combination with concurrent NVB and CBP chemotherapy. The toxicity of this
chemoradiotherapy regimen could be tolerated. A phase II trial is recommended to further evaluate the efficacy and
safety of this regimen.
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Locally advanced non-small cell lung cancer (NSCLC)
accounts for approximately 1/3 of NSCLC cases, and
challenges remain with respect to the treatment of this
form of NSCLC [1]. In the treatment of locally advanced
NSCLC, sequential chemoradiotherapy exhibits greater
efficacy than radiotherapy alone [2], whereas concurrent
chemoradiotherapy exhibits greater efficacy than se-
quential chemoradiotherapy [3-5]. Therefore, at present,
concurrent chemoradiotherapy is the standard treatment
for locally advanced NSCLC [1,5].
In particular, compared with sequential chemora-
diotherapy, concurrent chemoradiotherapy achieves im-
proved overall survival (OS), producing absolute benefits
in 3-year OS and 5-year OS of 5.7% and 4.5%, respect-
ively; this increase in OS may primarily be attributed to
improved locoregional control [5]. At present, concur-
rent chemoradiotherapy for locally advanced NSCLC
involves a standard radiation dose of 60 Gy with conven-
tional fractionation. To achieve more effective results,
the Radiation Therapy Oncology Group (RTOG) and the
North Central Cancer Treatment Group (NCCTG)
conducted studies (RTOG 0117 and NCCTG 0028, re-
spectively) to examine dose escalation with conventional
fractionation; these phase I/II trials determined that
doses of 74 Gy could be tolerated and generated en-
couraging survival results [6,7]. However, the results of
the subsequent phase III randomised controlled study
(RTOG 0617) were disappointing and difficult to com-
prehend. In this trial, less favourable survival outcomes
were observed for the 74 Gy high-dose group than for
the 60 Gy low-dose group, with one-year OS rates of
70.4% and 81%, respectively; moreover, because prelim-
inary analyses revealed no significant differences in tox-
icity between the high-dose group and the low-dose
group, these results did not reflect excessive treatment
toxicity for the high-dose group [8]. NSCLC involves
rapidly proliferating cells that exhibit a cell doubling
time of only 2.5-3.3 days, and accelerated repopulation
occurs during radiotherapy. If the duration of radiother-
apy treatments extends for longer than six weeks, each
additional day of treatment is associated with a 1.6% de-
crease in survival [9]. Although the exact reasons why
high-dose radiotherapy in the RTOG 0617 study failed
to produce survival benefits remain unclear, one poten-
tial factor that merits consideration is the long treatment
time of 7.4 weeks that is involved in conventional frac-
tionation [1].
Studies have demonstrated that higher biologically ef-
fective doses (BEDs) of radiotherapy in cancer treatments
will improve local control and survival [10,11]. Because
dose escalation with conventional fractionation requires a
significant increase in treatment time, two methods to im-
prove BED that maintain or reduce treatment time havebeen explored: hyperfractionation and hypofractionation.
Certain hyperfractionation radiotherapies for NSCLC have
achieved good clinical efficacy, including hyperfractionated
accelerated radiotherapy (HART) and continuous HART
(CHART). However, these therapies not only exhibit acute
toxicity but also involve multiple treatments per day that
produce inconvenience and more economic costs for pa-
tients; thus, it is not convenient for clinical applications of
these therapeutic techniques [12,13]. Advances in modern
radiotherapy techniques have led to the development of
three-dimensional conformal radiotherapy. Compared to
prior radiotherapy approaches, three-dimensional con-
formal radiotherapy can significantly lower the doses of
radiation to normal tissues, allowing for the administra-
tion of larger doses per fraction on tumors. Accelerated
hypofractionated irradiation at 3 Gy per fraction is fre-
quently used for the treatment of locally advanced
NSCLC [14-16]; under certain conditions, the dose of
radiation used in this approach can be incremented to
75 Gy [16]. To the best of our knowledge, no studies
have examined 3 Gy/fraction radiotherapy with con-
current chemotherapy. The purpose of this phase I trial
was to determine the maximum tolerated dose (MTD)
of accelerated hypofractionated three-dimensional con-
formal radiotherapy (at 3 Gy/fraction) that is admi-
nistered in combination with concurrent vinorelbine
(NVB) and carboplatin (CBP) chemotherapy for the
treatment of unresectable stage III NSCLC.
Methods
Eligibility
Patients with previously untreated unresectable stage
IIIA or stage IIIB NSCLC (as defined by the 2009 staging
standards of the International Union Against Cancer
(UICC)) were recruited, who were confirmed pathologic-
ally or cytologically. The patients had to be older than
18 years of age and no more than 75 years of age. The
Karnofsky performance status (KPS) scores of these pa-
tients were at least 70, and the patients were expected to
survive for at least 3 months. With respect to laboratory
test results, the patients possessed absolute neutrophil
counts (ANCs) of at least 2.0×109/L; haemoglobin levels
of at least 100 g/L; platelet counts (PLTs) of at least
100×109/L; and serum creatinine, alanine aminotrans-
ferase, aspartate aminotransferase, and total bilirubin
levels that were below the upper limit of the normal
range. No significant electrocardiography (ECG) abnor-
malities and no requirement hospitalisation for diseases
other than NSCLC.
Exclusion criteria: pregnant or breastfeeding; with ma-
lignancies other than NSCLC, with the exception of
cases of cervical carcinoma in situ or non-malignant
melanoma skin cancer that had been clinically cured for
at least five years; who could not undergo concurrent
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either superior vena cava syndrome or severe lung disor-
ders that affected lung function.
This clinical trial was approved by the Ethics Com-
mittee of Hebei Medical University. This study was
performed in accordance with the standards for human
clinical trials and the principles stated in the Declar-
ation of Helsinki (as issued in 1975 and revised in
2000). All patients signed an informed consent form
prior to enrolment.
Patient assessment
All patients underwent medical assessments within 2 weeks
prior to the start of treatment that included the acquisition
of a complete medical history; a complete physical exa-
mination; thoracoabdominal contrast-enhanced computed
tomography (CT); CT or magnetic resonance imaging
(MRI) of the brain; ECG; and a bronchoscopy. If clinically
indicated, a whole-body bone scan was obtained by emis-
sion CT (ECT), routine blood testing was performed, and a
comprehensive blood biochemical profile was acquired.
Patients underwent a physical examination and routine
blood testing each week (with increased examination fre-
quencies as necessary). Full biochemical profiles were
obtained and ECG was performed prior to each chemo-
therapy cycle.
Study design
This phase I trial was an open-label, non-randomised
study of radiation dose escalation. The primary endpoint
of the study was the determination of the MTD for
accelerated hypofractionated three-dimensional conformal
radiotherapy (at 3 Gy/fraction) administered in combi-
nation with concurrent NVB and CBP chemotherapy. The
secondary endpoints included short-term efficacy and
progression-free survival (PFS). Each cohort included at
least three cases treated with escalating-dose radiotherapy
and fixed-dose chemotherapy; the chemoradiotherapy
treatment scheme is depicted in Table 1.Table 1 Concurrent chemoradiotherapy schema
Concurrent chemoradiotherapy schema
RT regimen: Weeks 1–5: 3 Gy/f, 1 f/d,5 f/w; Dose escalation




Chemotherapy: NVB (25 mg/m2) d1, d8; CBP,AUC = 5 mg/m1.min
on d8, repeated every 28 d
NVB ◆ ◆ ◆ ◆
CBP ● ●Radiation therapy
Patients received radiotherapy in the supine position with
their hands folded on top of their heads. A vacuum pad
was used to immobilise a patient’s body position and ap-
propriately limit respiratory motion. Contrast-enhanced
spiral CT (GE Light Speed Plus 4) was performed in the
treatment body position. The image data were input into
the three-dimensional treatment planning system. The
Venus 5014 software package (Shanghai Tuoneng Co.,
Shanghai, China) was employed to design the radiotherapy
plan, using convolution algorithms. The delineation of the
target volume was performed in accordance with the con-
sensus guidelines for the delineation of radiotherapy tar-
gets in NSCLC [17]; in particular, the target area of the
primary lesion was delineated in the routine lung window
(1600, -600 Hounsfield units (HU)), and the mediastinal
target area was delineated in the mediastinal window (400,
20 HU). The treatment regimen utilised involved-field ra-
diation without elective nodal irradiation. Target volumes
were defined as follows: the gross tumour volume
(GTV) was defined as the primary lesion and lymph
nodes with short diameters of greater than 1 cm in CT
imaging; the clinical target volume (CTV) was defined
as the GTV enlarged by margins of 6 mm (in cases of
squamous cell carcinoma and metastatic lymph nodes)
or 8 mm (in cases of adenocarcinoma); the planning
target volume (PTV) was defined as the CTV enlarged
by a margin of 10 to 15 mm based on the respiratory
movement observed in the simulator. The GTV was
confirmed by two radiation oncologists and one diag-
nostic imaging specialist. The radiation oncologists
outlined vital organs and body surface contours. Three
to six coplanar or non-coplanar fields were utilised for
conformal radiation. Dose-volume histograms (DVHs)
were used to optimise the therapeutic plan. The follow-
ing limiting conditions for the radiation received by
vital organs were employed: the maximum V20 (the
percentage of healthy organ volume that receives 20 Gy
radiation) for both lungs was 30%; 0% of the oeso-
phagus was permitted to receive more than 70 Gy of ra-
diation; a maximum of 10 cm of the oesophagus was
permitted to receive 60 Gy or more of radiation; 0% of
the spinal cord should receive more than 40 Gy of radi-
ation; and the maximum V40 for the heart was 40%
[18]. The treatment utilised 6 MV X-rays from a Siemens
Primus Plus linear accelerator that was equipped with a
27-pair multi-leaf collimator (Topslane@_M, Shanghai
Tuoneng Co., Shanghai, China). All lesions were located
in a single target area if possible, and a second target area
was established to address distant lesions.
The full course of accelerated hypofractionated radio-
therapy was conducted at 3 Gy/fraction, once daily, with
five fractions per week; this radiotherapy regimen was
completed in 4.4-5 weeks.
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Chemotherapy began on the first day of radiotherapy. NVB
was administered by intravenous infusion at a dose of 25
mg/m2 on day 1 (d1) and day 8 (d8). CBP was administered
at an area under the concentration-time curve (AUC) of 5
mg/ml on d8. This treatment was repeated every 28 days.
At least one cycle of chemotherapy was performed concur-
rently with radiotherapy. After radiotherapy had concluded,
patients received a maximum of four cycles of consolidative
chemotherapy, utilising the same chemotherapy regimen
that was employed during the concurrent chemoradio-
therapy [18]. Anti-emetics, hepatoprotective drugs, and
other treatments were also administered.
Supportive care
To ensure the implementation of the chemoradiotherapy
regimen, patients whose ANCs decreased to less than 2.0 ×
109/L were treated with granulocyte colony-stimulating
factor (GSF) until their ANCs had increased to at least nor-
mal levels. Patients with PLTs of less than 75 × 109/L were
treated with interleukin-11 until PLTs had increased to at
least normal levels. Nutritional support via intravenous
rehydration was also provided to patients as necessary.
Dose escalation and determinations of dose-limiting
toxicity (DLT)
A limited number of reports address hypofractionated
radiotherapy with concurrent chemotherapy, and only the
European Organisation for Research and Treatment of
Cancer (EORTC) has performed a phase I study of this
therapeutic approach. This EORTC study determined that
this type of chemoradiotherapy approach should be safe at
a radiation dose of 66 Gy with fractions of 2.75 Gy; how-
ever, this investigation did not report an MTD and used
low doses of cisplatin alone as a chemotherapy regimen
[19]. In our previous studies of concurrent chemora-
diotherapy for lung cancer and oesophageal cancer, we
demonstrated that Eastern and Western patient popula-
tions exhibit different tolerances to chemoradiotherapy
[18,20,21]. In examinations of three-dimensional conformal
radiotherapy with conventional fractions of 2 Gy/f in com-
bination with concurrent NVB and CBP chemotherapy, we
found that radiation doses of 70 Gy could be tolerated
[18,21]. For this study, we therefore arbitrarily chose 66 Gy
as a starting radiotherapy dose with a 3 Gy increment. A
modified Fibonacci scheme was utilised for dose escalation
[18,22], and every cohort contained at least 3 patients. If
no dose-limiting toxicity (DLT) was observed after the com-
pletion of full-dose radiotherapy and at least concurrent one
cycle chemotherapy, the next dose level was applied. How-
ever, repeated administration to the same patient was not
allowed. If 1 of 3 patients treated within a dose level experi-
enced a DLT, 3 additional patients were treated at the same
level. If a second case of DLT was observed, the doseescalation was stopped, and the tested dose was defined as
the level of DLT. The MTD was defined as the dose level
below the dose that produced the DLT. Acute toxicity was
monitored for all three cases in each dose group for the first
90 days following the start of radiotherapy.
Treatment toxicity was evaluated in accordance with
the Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0, which have been issued by the Na-
tional Cancer Institute/National Institutes of Health (NCI/
NIH). Weekly assessments of toxicity occurred during the
concurrent chemoradiotherapy treatment. DLT was de-
fined as a severe and/or life-threatening adverse event that
influenced the implementation of concurrent chemora-
diotherapy. These adverse events included radiation pneu-
monitis of grade 3 or higher, oesophagitis of grade 3 or
higher, and other non-haematologic toxicities of grade 3
or higher (with the exception of grade 3 nausea, vomiting,
fatigue, and/or weight loss); grade 3 febrile neutropenia;
grade 4 neutropenia; grade 3 or grade 4 thrombocyo-
tpenia; grade 3 or grade 4 anaemia; and any grade 5 ad-
verse effects [18].
Evaluations of short-term tumour treatment efficacy
Evaluations of short-term treatment efficacy were per-
formed by examining thoracoabdominal spiral CT re-
sults at four weeks after the completion of radiotherapy;
the Response Evaluation Criteria in Solid Tumours, ver-
sion 1.1 (RECIST 1.1), standard was utilised for these
assessments [23].
Dose attenuation
Dose attenuations were implemented based on the most
serious adverse events that occurred at any point after
the start of treatment.
Because we were conducting a radiotherapy dose escal-
ation study, no reductions in radiation dose were permit-
ted. However, if toxicity of grade 3 or higher occurred
(with the exception of grade 3 nausea, vomiting, or weight
loss), radiotherapy was postponed until the toxicity had
been resolved. In contrast, if adverse events occurred that
were unrelated to radiotherapy, such as peripheral neur-
opathy, the radiotherapy was continued but chemotherapy
was suspended. The chemotherapy was resumed after
these adverse events had dissipated.
The following chemotherapy dose attenuation proce-
dures were employed. In the event of grade 3 or grade 4
thrombocytopenia, grade 3 or grade 4 anaemia, grade 4
neutropenia, or grade 3 or grade 4 non-haematologic tox-
icities (except for grade 3 nausea, vomiting or weight loss),
both radiotherapy and chemotherapy were suspended until
the toxicity had been resolved. If the toxicity had not been
resolved within two weeks, the patient was withdrawn
from the study. The NVB and CBP doses of this patient’s
subsequent chemotherapy cycle were reduced by 25%, and































Table 3 Radiation dose escalation schema
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tient exhibited grade 3 neutropenia or grade 2 thrombocy-
topenia, chemotherapy was stopped but radiotherapy was
continued. The NVB and CBP doses of this patient’s subse-
quent chemotherapy cycle remained unchanged, and the
patient received prophylactic GSF treatment [18].
Follow-up and statistics
Follow-up was conducted every three months for the first
two years after the completion of radiotherapy and every
six months thereafter. All statistical analyses were per-
formed using the SPSS 19.0 biostatistical software package.
The survival data were evaluated using the Kaplan-Meier
method. The survival time was measured from the ini-
tiation of the concurrent chemoradiotherapy until death
due to any cause or the last follow-up. Only the initial in-
stance of treatment failure was considered with respect to
assessing causes of treatment failure. PFS was defined as
survival without local recurrence or distant metastases.
Results
Patients characteristics
From August 2010 to October 2012, 13 patients with
pathologically or cytologically confirmed cases of previ-
ously untreated NSCLC were enrolled into this study. All
13 patients underwent toxicity and efficacy evaluations.
The patient characteristics are provided in Table 2. The
median age of was 65 years, and their median KPS score
was 80. The 13 cases included seven cases of squamous
cell carcinoma and 6 cases of adenocarcinoma. There were
six cases of stage IIIA cancer and seven cases of stage IIIB
cancer. The median GTV was 84.6 cm3 (with a mean of
97.2 cm3 and a range of 22.3-222.5 cm3), and the median
PTV was 234.9 cm3 (with a mean of 242.7 cm3 and a
range of 111.6-369.7 cm3).
Compliance
All patients received escalating-dose radiotherapy at one
of the three dose levels of 66 Gy, 69 Gy, and 72 Gy; in
particular, three, six, and four patients, respectively, were
enrolled at these dose levels, as presented in Table 3. All
of the patients completed the radiotherapy dose and re-
ceived at least one cycle of concurrent chemotherapy.
All 13 patients received consolidative chemotherapy
with a median of four chemotherapy cycles (with a range
of one to four cycles).
Non-haematologic toxicity
Radiation pneumonia and radiation oesophagitis were
commonly observed, although the majority of cases of
these toxicities were mild. Among the whole group,
there was only one case of grade 3 radiation pneumon-
itis and two cases of grade 3 radiation oesophagitis.
Nausea, vomiting, fatigue, and anorexia were observedin most of cases; however, these adverse effects were
mild and were successfully alleviated without affecting
the implementation of chemoradiotherapy through the
administration of appropriate antiemetics and intraven-
ous rehydration. Liver and kidney toxicity was rare.
Detailed information regarding the non-haematologic
toxicities is provided in Table 4.
Haematologic toxicity
All patients exhibited neutropenia; in particular, 76.9% of
cases exhibited grade 1 or grade 2 neutropenia, only 15.3%
of the patients exhibited grade 3 neutropenia, and only one
patient exhibited grade 4 neutropenia. Thrombocytopenia
Table 4 Nonhematologic toxicity
Toxicity 66 Gy 69 Gy 72 Gy Total
Case Case Case Case (%)
Radiation pneumonia 10(76.9)
I 1 2 1
II 1 2 2
III 0 0 1
Radiation oesophagitis 11(84.6)
I 1 2 1
II 1 3 1
III 0 0 2
Radiation dermatitis 9(69.2)
I 1 3 3
II 0 1 1
Nausea 12(92.3)
I 1 2 1
II 1 2 1
III 1 1 2
Vomiting 8(61.5)
I 1 1 2
II 1 1 1
III 0 1 0
Anorexia 12(92.3)
I 1 1 1
II 2 2 1
III 0 2 2
Fatigue 11(84.6)
I 0 3 1
II 1 2 2
III 1 0 1
ALTI 0 1 2 3(23.1)
ASTI 1 0 2 3(23.1)
Cr I 1 0 1 2(15.4)
BIL I 0 1 0 1(7.7)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cr: serum
creatinine; BIL: bilirubin.
Table 5 Hematologic toxicity
Toxicity 66 Gy 69 Gy 72 Gy Total
Case Case Case Case (%)
Neutropenia 13(100)
I 1 2 1
II 2 2 2
III 0 2 0
IV 0 0 1
Thrombocytopenia 8(61.5)
I 1 2 1
II 1 1 2
Anemia 8(61.5)
I 1 3 2
II 1 0 1
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grade 2. The haematologic toxicities observed in this study
are detailed in Table 5.
The determination of the MTD
Three patients were initially enrolled into the 66 Gy
dose group, and none of these patients experienced
DLT. Similarly, three patients were initially enrolled
into the 69 Gy dose group, and none of these patients
experienced DLT. In contrast, three patients were ini-
tially enrolled into the 72 Gy dose group, and all of
these patients experienced DLT. In particular, onepatient exhibited grade 3 radiation pneumonitis, one
patient exhibited grade 3 radiation oesophagitis, and
one patient exhibited grade 4 neutropenia. To confirm
these findings, the enrolment of three additional pa-
tients at the 72 Gy dose level was planned; however,
the single patient who was first enrolled to achieve this
purpose experienced a DLT involving grade 3 radiation
oesophagitis. Moreover, adverse reactions occurred
more frequently in the 72 Gy group than in the
remaining dose groups; this group accounted for 52.9%
(9/17) of the grade 3 or grade 4 adverse reactions of
the entire study but only 30.8% (4/13) of the patients of
the study. However the occurrence of the grade 3 or
grade 4 adverse effects in the 66 Gy and 69 Gy dose
level was 47.1% (6/17) of the entire study but 69.2% (9/
13) of the patients of the study. These findings sug-
gested that the 72 Gy dose level could not be tolerated;
as a result, no additional patients were enrolled at the
72 Gy dose level. To confirm that the 69 Gy dose level
was safe, an additional three patients were enrolled at
the 69 Gy dose level, and none of these patients expe-
rienced DLT.
In accordance with the study design, because the 72
Gy dose level produced severe toxicities, including all
four patients at this dose level experiencing DLT, 72 Gy
was designated as the dose level at which DLT occurred;
thus, 69 Gy, as the highest tested dose that was less than
72 Gy, was regarded as the MTD.
Short-term treatment efficacy
Evaluations of the short-term treatment efficacy among
the 13 study participants revealed that 23.1% (3/13) of
participants exhibited a complete response (CR), 61.5%
(8/13) of participants exhibited a partial response (PR),
15.4% (2/13) of participants exhibited a stable disease
(SD) state, and no cases exhibited a progressive disease
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therefore 84.6% (11/13).
Survival
Although this study is merely a phase I trial, we none-
theless determined preliminary survival results. Because
of the short follow-up period (from four to 20 months),
which included a median follow-up period of 10 months,
only three deaths occurred; however, mature OS data
have not yet become available. The median PFS was 12
months, and 49.4% of 1-year PFS (Figure 1). Recurrence
or progression occurred in six of the examined cases, in-
cluding one case of recurrence within the radiation field,
one case involving recurrence within the radiation field
and distant metastasis (liver metastasis), and four cases
of distant metastases (two cases of brain metastasis, one
case of liver metastasis and bone metastasis, and one
case of adrenal metastasis).
Discussion
Radiotherapy is one of the most important treatments
for NSCLC, and radiation dose levels significantly affect
treatment outcomes. Fletcher [24] believed that a radio-
therapy dose of 80–100 Gy was required to cure lung
cancer. This assume has been confirmed through a clinical
trial of stereotactic body radiotherapy, which indicated that
significantly higher survival rates were observed amongFigure 1 The median PFS time was 12 months, and 1- year PFS rate 4patients who were treated with a BED of at least 100 Gy
than among patients who were treated with a BED of less
than 100 Gy [25]. Relative to traditional radiotherapy ap-
proaches, the techniques of three-dimensional conformal
radiotherapy and intensity-modulated radiotherapy can sig-
nificantly reduce the radiation doses that are received by
normal tissues and organs; in the context of radiotherapy
alone (without accompanying chemotherapy), these tech-
niques allow tolerable toxicity to be achieved even at radi-
ation doses as high as 83.3 Gy or 103 Gy [26,27]. NSCLC
cells demonstrate accelerated repopulation during radio-
therapy, and increases in treatment duration can therefore
reduce local control, negatively impacting survival. Thus,
to improve local control it is critical to achieve higher
BEDs at constant or reduced overall treatment durations
[9,28]. However, hyperfractionated radiotherapy not only
produces more severe acute reactions than conventional
radiotherapy but also requires three treatments per day,
producing inconvenience and much more treatment costs
for patients; thus, it is not easy to clinically utilise hyper-
fractionated radiotherapies [12,13].
Mehta et al. [9] suggested that for cancers with very
short cell doubling times, such as NSCLC, increasing
the dose per fraction constitutes a promising method of
achieving dose escalation. In cases of stage I/II NSCLC,
hypofractionated stereotactic radiotherapy has achieved
effects comparable to the results of surgery; in these9.4%.
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doses of up to 18–22 Gy per fraction [29,30]. However,
in cases of locally advanced NSCLC, because of concerns
regarding toxicities (particularly late toxicities) to the
oesophagus, trachea, ribs, nerves, and other vital organs,
it has not been possible to achieve these high doses per
fraction [30]. In fact, the appropriate dose for hypo-
fractionated radiotherapy for locally advanced NSCLC
remains unclear [1].
Thirion et al. [31] conducted a study of accelerated
hypofractionation using 3 Gy per fraction in which a 72
Gy radiation dose was delivered in 24 fractions over five
weeks. The 25 NSCLC cases that Thirion et al. examined
included 16 cases of stage III NSCLC. In the investiga-
tion conducted by Thirion et al., one case experienced
grade 3 radiation pneumonitis, two experienced grade 3
radiation oesophagitis, and no grade 4 or higher adverse
events occurred among the entire group. Xie et al. [16]
performed a dose escalation trial of accelerated hypo-
fractionated radiotherapy with 3 Gy increments using
cases from the Chinese population and found that pa-
tients could tolerate the radiotherapy treatment at doses
of up to 75 Gy at V20 levels of no greater than 20% or
at doses of up to 69 Gy at V20 levels of between 20%
and 30%. The Fudan University Cancer Centre reported
the results of a Phase II trial of accelerated hypo-
fractionated radiotherapy with sequential chemotherapy
for NSCLC [32]. In this trial, the initial radiation dose
was 50 Gy with 2.5 Gy fractions; the dose was subse-
quently increased at 3 Gy/fraction to a total radiation
dose of 65 to 68 Gy, and elective nodal irradiation was
not performed. All patients received 2 cycles of induc-
tion chemotherapy (with full-dose NVB and cisplatin),
and good treatment efficacy was observed. The median
PFS, median OS, and three-year OS were 10 months,
19.0 months, and 32.1%, respectively, with acceptable
treatment toxicities.
Conventional fractionated radiotherapy with concurrent
chemotherapy achieves superior efficacy to sequential
chemoradiotherapy; moreover, experimental studies have
demonstrated that hypofractionated radiotherapy com-
bined with chemotherapy can achieve significantly in-
creased biological effects [33]. Therefore, compared with
these treatments, accelerated hypofractionated radio-
therapy combined with concurrent chemotherapy should
theoretically be capable of producing additional increases
in therapeutic efficacy. However, due to concerns that
hypofractionated radiotherapy with concurrent chemo-
therapy could have aggressive toxicity, little research has
been conducted in this area. In addition, investigations of
this topic have utilised very different fractionation regi-
mens and concurrent chemotherapy drugs. In particular,
the studied doses per fraction have ranged from 2.4 Gy to
2.75 Gy, and the concurrent chemotherapy drugs haveincluded low daily doses of cisplatin, weekly paclitaxel/
CBP, and full-dose NVB/cisplatin [19,34-36].
An EORTC study reported dose escalation results from
hypofractionation radiotherapy with 2.75 Gy fractions for
NSCLC and suggested that radiotherapy with a total dose
of 66 Gy in 24 fractions in combination with concurrent
low-dose cisplatin could be well tolerated [19]. Based on
these results, a phase III randomised study was conducted
to compare concurrent chemoradiotherapy with sequen-
tial chemoradiotherapy [34]. Because this study adminis-
tered elective nodal irradiation, high rates of severe acute
oesophagitis were observed among the concurrent group;
in particular, grade 3 and grade 4 acute oesophagitis was
observed in 14% and 3%, respectively, of the patients in
concurrent group, whereas significantly lower rates of
acute oesophagitis were observed in the sequential group.
Interestingly, rates of late oesophageal injury were not sig-
nificantly higher in the concurrent group (5%) than in the
sequential group (4%). The OS did not differ between the
two groups; in particular, the concurrent group and the
sequential group exhibited 2-year OS of 39% and 34%, re-
spectively, and three-year OS of 34% and 22%, respect-
ively. This lack of improvement in OS with the concurrent
therapy compared to the sequential therapy may relate to
the low doses of chemotherapy that were administered in
this study. A 2011 report of the American Society of Clin-
ical Oncology (ASCO) discussed the preliminary results of
a British study of radiotherapy with concurrent two-drug
chemotherapy for NSCLC, using a total radiation dose of
55 Gy in 20 fractions with 2.75 Gy/fraction; in particular,
this treatment produced a median survival time (MST) of
27.4 months, a 2-year OS of 54%, and a 3-year OS of 38%
[35]. In this study, full-dose of chemotherapy drugs were
administered in a regimen that included 15 mg/m2 NVB
on d1, d6, d15, and d20 as well as 20 mg/m2 cisplatin on
d1-4 and d16-19 [36]. A phase II trial by the Korean Radi-
ation Oncology Group also achieved good survival results,
including an MST of 28.1 months and 2- and 3-year OS of
56.4% and 43.8%, respectively [37]. This study used a
radiotherapy regimen consisting of a total radiation dose
of 60 Gy in 25 fractions of 2.4 Gy/fraction, which was
combined with concurrent paclitaxel and CBP chemother-
apy. Elective nodal irradiation was not performed, and tol-
erable toxicity was observed.
The aforementioned three regimens of hypofractionated
radiotherapy with concurrent chemotherapy involved sig-
nificant differences in radiotherapy fractionation, total ra-
diation dose, and concurrent chemotherapy protocols. In
addition, distinct inclusion criteria were used in these
studies, and different restrictions on the radiation dose
received by normal tissues and organs were employed.
Thus, it is difficult to horizontally compare the advantages
and disadvantages of these prior investigations to identify
a regimen that could receive widespread acceptance.
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radiotherapy with concurrent chemotherapy exhibits good
comparability with the efficacy of conventional fraction-
ation with concurrent chemotherapy [3-5].
In our trial, we chose 3 Gy as the dose per fraction be-
cause the use of hypofractionated radiotherapy at 3 Gy per
fraction was a relatively mature approach for radiation
treatment alone; in addition, the chosen radiotherapy regi-
men was efficient and was expected to be completed in a
total treatment time of five weeks. Thus, this regimen
could achieve a high rate of tumour control [9]. This
phase I trial revealed that hypofractionated radiotherapy at
3 Gy/fraction with concurrent full-dose chemotherapy
exhibited high levels of safety. No treatment-related deaths
occurred during the entire study. The main toxicities that
were observed included radiation oesophagitis and radi-
ation pneumonitis. The rate of radiation oesophagitis
reached 84.6% (11/13) in whole group. Because we utilised
the involved-field irradiation technique and refrained from
administering elective nodal irradiation, the observed
cases of radiation oesophagitis were mainly of grade 1 or
grade 2 (69.2%, 9/13). The adverse events to the radiother-
apy were tolerable after general symptomatic treatment
and did not affect the implementation of the radiotherapy
regimen. The 2 observed cases of grade 3 radiation
oesophagitis occurred at the 72 Gy dose level. One case of
grade 3 radiation pneumonitis occurred in the 72 Gy
group, whereas the other observed cases of radiation
pneumonitis in this study were all grade 1 or grade 2.
Other non-haematologic toxicities were easily managed
through clinical treatment and did not affect the imple-
mentation of concurrent chemoradiotherapy. Although all
patients suffered from neutropenia, most of the cases of
these adverse events were mild and did not affect the im-
plementation of concurrent chemoradiotherapy. Only one
case of grade 4 neutropenia occurred in this study, and
this case arose in the 72 Gy group. In this case, after the
administration of treatments to prevent infection and GSF
to enhance white blood cell counts, agranulocytosis was
resolved within one week, and no serious consequences
were observed. Mild degrees of anaemia and throm-
bocytopenia were observed in the whole group. The short-
term tumour control rate of 84.6% indicated that our regi-
men of hypofractionated radiotherapy with concurrent
chemotherapy was able to achieve good local tumour con-
trol. Because of the short follow-up time and the small
number of examined cases, mature OS data for this study
are not yet available; however, the 12-month PFS of this
investigation is highly comparable to the 12-month PFS
results from other studies [32].
Conclusions
Accelerated hypofractionated three-dimensional conformal
radiotherapy (at 3 Gy/fraction) combined with concurrentNVB and CBP chemotherapy is feasible and safe for the
treatment of unresectable stage III NSCLC. The MTD of
the radiotherapy was 69 Gy in 23 fractions; at this dose, ad-
verse events could be tolerated. Based on this phase I trial,
a phase II trial of a hypofractionated radiotherapy approach
involving a total radiation dose of 69 Gy in 23 fractions
with 3 Gy/fraction that is administered in combination
with concurrent chemotherapy is ongoing to further evalu-
ate the efficacy and safety of this treatment regimen.
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